Ellipses Pharma
Geoff Fisher is an experienced professional in the pharmaceutical and medical marketing industries, currently serving as the Director of Clinical Strategy at Ellipses Pharma since November 2021. Previously, Geoff established geoFish Medical Marketing Ltd in June 2013, working with various clients, including global pharmaceutical and biotechnology companies, to develop strategic medical affairs plans and support launch brands, particularly in oncology. Prior roles include Global Medical Affairs Leader at AstraZeneca, where responsibilities encompassed the development of target product profiles and comprehensive medical affairs strategies across emerging oncology portfolios. Additional experience includes leadership in clinical development and medical affairs at Gardiner Caldwell Communications, GlaxoSmithKline, and GlaxoWellcome, with a strong focus on regulatory approval processes and strategic medical communications. Geoff holds a PhD in Oncology from De Montfort University and a BSc Hons in Applied Biology from Coventry University.
This person is not in any teams
This person is not in any offices
Ellipses Pharma
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments. Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients. Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.